ARLINGTON, Va., Feb. 11, 2025 /PRNewswire/ -- Today, the American diabetes Association® (ADA) announced the awardees of the 2025 Pathway to Stop Diabetes® (Pathway) grants. This year's grants dedicate ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks and strokes in survivors.

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Researchers have identified a group of brain cells in mice that play a key role in regulating appetite. These neurons, ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.

Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

HMB is produced naturally in our bodies during the metabolism of the essential amino acid leucine. While many of HMB’s ...